VJOncology is committed to improving our service to you

ESMO 2018 | More evidence needed to support checkpoint inhibitor use in late-stage cancer

VJOncology is committed to improving our service to you

Giorgio Scagliotti

Giorgio Scagliotti, MD, PhD, of the University of Torino, Torino, Italy, discusses the considerable improvement in progression free survival (PFS) in a small subgroup of non-small cell lung cancer (NSCLC) patients on immune checkpoint inhibitors. Pembrolizumab alone seemed to be superior to chemotherapy for high PD-L1 expressing tumors. Bringing attention to insufficient evidence, Dr Scagliotti proposes that a diverse therapeutic portfolio is critical to managing and treating stage 4 disease. This interview was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter